Overview

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults. A gatekeeper strategy will be employed for sequentially testing the secondary objectives. This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atomoxetine Hydrochloride